Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches

Figure 1 The range increased incidence of post-transplant lymphoproliferative disorders in various transplants. Incidence in intestinal transplant and in multi-organ transplants it is < 20%, while in hematopoietic stem-cell transplant it is > 20% with selective T-cell depletion[4]. HSCT: Haplo-identical allogeneic hematopoietic stem-cell transplant.

Figure 2 Incidence of post-transplant lymphoproliferative disorders after allogenic hematopoietic stem-cell transplant. An additional risk factor in hematopoietic stem-cell transplantation is: recipient age of > 50 yr[4]. HSCT: Haplo-identical allogeneic hematopoietic stem-cell transplant.

Figure 3 Risk factors for the development of post-transplant lymphoproliferative disorders after solid-organ transplantation[4]. MO: Multi-organ.

Figure 4 Epstein-Barr virus positivity among various types of post-transplant lymphoproliferative disorders[4]. EBV: Epstein-Barr virus.

Figure 5 Clinical manifestations of post-transplant lymphoproliferative disorders[2]. GIT: Gastrointestinal tract; CNS: Central nervous system.

Figure 6 Common locations of post-transplant lymphoproliferative disorder involvement[1]. GIT: Gastrointestinal tract; CNS: Central nervous system.

Figure 7 Development of rituximab-based treatment strategies for post-transplant lymphoproliferative disorders after solid organ transplantation: Sequential (2002-2008) vs risk-stratified sequential (2006-2014) treatment[23,65].

Figure 8 Incidence of graft post-transplant lymphoproliferative disorder involvement[4,27]. KTR: Kidney transplant recipients; GIT: Gastrointestinal tract; TR: Transplant recipients.